Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Aug - Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.
Source: Bse
Nectar Lifesciences Limited (NECLIFE)
Small CapPharma stocks · Small cap · NSE
Nectar Lifesciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result14 Aug, 08:47 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
63BullishSMA20 -10.3% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 40
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
NECLIFED candles · FIT view-6.2%Latest close ₹11.06 on 2026-10-19
Bar
+1.5%
RSI
56
MACD hist
0.05
52W pos
13%
2026-10-19O ₹10.90H ₹11.06L ₹10.85C ₹11.06Vol 1.6L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NECLIFENifty PharmaNifty 500
- NECLIFE
- +2.4%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +8.0 pp
Chart stats
19 Oct 2026- From 52W high
- -50.6%
- 52W range position
- 13%
- ATR (14)
- 4.4%
- Volume vs 20D
- 1.21x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹10 - ₹11.2
₹22.4
₹9.3 - ₹22.4
₹0.5
Latest completed session
20-session average
40.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED25
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -100.0% · PAT NDF YoY
Technical
Bullish63
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence59
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -100% YoY · margin compression
Filed 14 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0 Cr | -100.0% | -100.0% |
| EBITDA | ₹-27 Cr | -2600.0% | +52.6% |
| Operating margin | -6198.0% | -618200 bps | -176100 bps |
| PAT | ₹-15 Cr | NDF | NDF |
| PAT margin | NDF | NDF | NDF |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.35
- EV/EBITDA
- —
- Market Cap
- 204.00Cr
Profitability
- ROE
- -31.30%
- ROCE
- 0.05%
- ROA
- -39.39%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -20.00%
- EPS 5Y
- -20.00%
- Revenue 3Y
- -24.00%
- EPS 3Y
- -24.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- -2.39×
- Altman Z
- 4.21
- Book Value
- 30.00
Cash Flow
- FCF Yield
- 421.08%
- FCF Positive Y
- 11/5
- OCF
- -349.00 Cr
- EPS TTM
- -11.50
Shareholding
- Promoter Hold
- 51.84%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 10%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 0.0-100.0% vs prev
Net Profit
₹ CrLatest: -15.0+77.9% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 56. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~11.5% over last month) — short-term momentum negative.
- RSI(14) at 56 — rising, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 51% off 52W high · 19% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
38
RS percentile
Stage 4 Downtrend
1M return
+0.7%
3M return
+2.4%
6M return
-9.5%
1Y return
-26.3%
RS 1D
+6
RS 20D
+5
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 2.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.3%.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 79.04+6.02%
RS vs Nifty 50079
Valuation & peers
U-Score 25 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 25 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation5/30
Growth1/25
Quality0/20
Balance Sheet11/15
Cash Flow9/10
Piotroski
3/9 (+1)
Penalties
-2
Raw sum
25
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
25/100 · legacy band OVERVALUED
Positive drivers
- FCF yield is supportive at 421.1%.
- Cash flow contributes 9/10 to the score.
- Balance sheet contributes 11/15 to the score.
Main drags
- Penalty bucket subtracts 2 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 1/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.3
EV/EBITDA
—
ROE
-31.3%
ROCE
0.1%
FCF Yield
421.1%
Debt/Equity
0.0
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
25
Previous: 25
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
25
25
25
25
25
25
25
25
25
25
25
25
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
2.4
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
LOTUSEYE
Small
Lotus Eye Hospital and Institute Limited
Healthcare Services
match 165
13
1504.0
0.1%
-161992%
OVERVALUED
NATCAPSUQ
Small
Natural Capsules Limited
Healthcare Services
match 164
52
13.5
6.5%
+71%
FAIR VALUE
LYKALABS
Small
Lyka Labs Limited
Healthcare Services
match 164
20
—
-10.2%
—
OVERVALUED
MEDICO
Small
Medico Remedies Limited
Healthcare Services
match 163
65
13.0
19.0%
+71%
UNDERVALUED
VINEETLAB
Small
Vineet Laboratories Limited
Healthcare Services
match 160
5
65.0
3.7%
-1551%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Nectar Lifesciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
59Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 25th percentile of the scored universe and 16th percentile within Pharma. Main check: results consistency is weak at 5/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
11 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
25th percentile
overall median 67 · Pharma: 16th pctile, median 70 · Small: 28th pctile, median 66
Evidence depth
Financial-only
11 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
82
strong · holding, pledge, alignment
Cash flow
74
acceptable · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
5
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 6.9%.
- ▸FCF yield is 362.5%.
- ▸11 years of positive FCF.
Trust risks
- ▸Operating cash flow is negative at ₹-349 Cr.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 0.1%.
- ▸ROE is low at -31.3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Nectar Lifesciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Jun - Please find attached herewith copy of newspaper publication as per Section 124(6) of Companies Act, 2013
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Jun - Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March …
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.